Journal article
Scheduled versus Pro Re Nata Dosing in the VIEW Trials
Gisbert Richard, Jordi Mones, Sebastian Wolf, Jean Francois Korobelnik, Robyn Guymer, Michaella Goldstein, Christiane Norenberg, Rupert Sandbrink, Oliver Zeitz
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2015
Grants
Funding Acknowledgements
The author(s) have made the following disclosure(s): G.R.: Financial support - Bayer HealthCare (Berlin, Germany), Pfizer (Cambridge, MA), Carl Zeiss Meditec (Jena, Germany), Novartis AG (Basel, Switzerland), Pixium Vision (Paris, France); Consultant - Carl Zeiss Meditec (Jena, Germany), Pixium Vision (Paris, France).